This preprint reports an in-silico effort to discover inhibitors of the Mycobacterium tuberculosis enzyme Ag85C, a target of interest in antitubercular drug development. The authors combined primary molecular docking, pharmacophore modeling, and ADME/pharmacokinetics assessment to prioritize compounds for further study. The work aims to provide a rational, computational pipeline to identify candidate molecules that interact with Ag85C and have favorable early drug-like properties.
The study employed a tiered computational workflow. First, primary molecular docking was used to evaluate how a set of compounds fit within the active site of Ag85C and to estimate relative binding affinities and interactions with active-site residues. Next, the authors constructed a pharmacophore model that defines essential spatial and chemical features required for binding. That pharmacophore was then used to screen a library of antituberculotic compounds. Finally, shortlisted molecules underwent more extensive docking and were evaluated for ADME and pharmacokinetic properties to assess early drug-likeness and absorption potential.
In the primary docking stage, the clinically relevant nitroimidazole drugs Delamanid and Pretomanid emerged as the top hits. According to the abstract, both drugs demonstrated strong predicted binding affinities and formed interactions with key active-site residues of Ag85C. The preprint highlights these two molecules as high-ranking compounds from the initial docking screen. The abstract does not report the precise docking scores or the exact residues involved; those details appear to be reported in the full manuscript.
A pharmacophore model was developed to represent the essential binding features identified from docking and structural analysis. This model served as a filter to identify compounds that present the required arrangement of pharmacophoric features for Ag85C engagement. The pharmacophore-based screen was applied to a library of 4,254 antituberculotic compounds. The model-based filtering narrowed the search space to candidates matching the defined binding motif, enabling focused downstream docking and ADME evaluation.
Applying the pharmacophore model and performing major docking studies on filtered compounds produced three prioritized candidates: F0314-0040, F0398-0505, and F0349-2716. These three compounds exhibited high binding affinities in the study’s subsequent docking analyses and were highlighted as promising leads for Ag85C inhibition. The abstract states that these compounds showed favorable docking results but does not include numeric affinity values, binding poses, or comparative ranking metrics in the summary; those specifics are in the preprint body and supplementary material.
Selected compounds, including the three prioritized leads, were subjected to in-silico ADME and pharmacokinetics analyses. The authors report that these candidates demonstrated favorable drug-likeness and absorption profiles, supporting their potential as effective antituberculotic agents. The abstract indicates positive early pharmacokinetic properties but does not provide explicit ADME parameter values (for example, predicted Caco-2 permeability, plasma protein binding, metabolic liabilities, or clearance estimates); readers should consult the full text for the complete ADME dataset.
The authors conclude that integrating primary docking, pharmacophore modeling, and ADME assessment offers a comprehensive, rational approach for early-stage antitubercular drug design targeting Ag85C. They highlight Delamanid and Pretomanid as top primary-docking hits and present three novel chemical entities—F0314-0040, F0398-0505, and F0349-2716—as promising leads following pharmacophore screening and major docking.
Because this report is a preprint, it has not undergone peer review. The abstract does not include quantitative docking scores, detailed interaction maps, or full ADME parameter tables; those data are expected in the full manuscript and supplementary material. Experimental validation (biochemical assays, cellular activity, and in vivo studies) is not described in the abstract and would be required to confirm the computational predictions and advance these candidates in the drug development pipeline.